Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey.
Natália Sousa Freitas Queiroz, Fábio Vieira Teixeira, Marina Pamponet Motta, Liliana Andrade Chebli, Adriano Akira Ferreira Hino, Camilla de Almeida Martins, Abel Botelho Quaresma, Alexandre Augusto de Paula da Silva, Adérson Omar Mourão Cintra Damião, Rogerio Saad-Hossne, Paulo Gustavo Kotze
Author Information
Natália Sousa Freitas Queiroz: Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, SP, Brazil.
Marina Pamponet Motta: School of Medicine, Federal University of Bahia, Salvador 40020-025, BH, Brazil.
Liliana Andrade Chebli: IBD Outpatient Clinics, Universidade Federal de Juiz de Fora, Juiz de Fora 36010-010, MG, Brazil.
Adriano Akira Ferreira Hino: Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80440-220, PR, Brazil.
Camilla de Almeida Martins: Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, SP, Brazil.
Abel Botelho Quaresma: Departamento de Ciências da Saúde, Universidade do Oeste de Santa Catarina (UNOESC), Joaçaba 89600-000, SC, Brazil.
Alexandre Augusto de Paula da Silva: Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80440-220, PR, Brazil.
Adérson Omar Mourão Cintra Damião: Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo 05403-000, SP, Brazil.
Rogerio Saad-Hossne: Botucatu Medical School, Paulista State University (UNESP), Botucatu 18600-050, SP, Brazil.
Paulo Gustavo Kotze: Health Sciences Postgraduate Program, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80440-220, PR, Brazil.
BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic is still evolving globally, and Brazil is currently one of the most affected countries. It is still debated whether patients with inflammatory bowel disease (IBD) are at a higher risk for developing COVID-19 or its complications. AIM: To assess geographical distribution of IBDpatients at the highest risk and correlate these data with COVID-19 mortality rates in Brazil. METHODS: The Brazilian IBD Study Group (Grupo de Estudos da Doença Inflamatória Intestinal do Brasil) developed a web-based survey adapted from the British Society of Gastroenterology guidelines. The included categories were demographic data and inquiries related to risk factors for complications from COVID-19. patients were categorized as highest, moderate or lowest individual risk. The Spearman correlation test was used to identify any association between highest risk and mortality rates for each state of the country. RESULTS: A total of 3568 patients (65.3% females) were included. Most participants were from the southeastern and southern regions of Brazil, and 84.1% were using immunomodulators and/or biologics. Most patients (55.1%) were at moderate risk, 23.4% were at highest risk and 21.5% were at lowest risk of COVID-19 complications. No association between the proportion of IBDpatients at highest risk for COVID-19 complications and higher mortality rates was identified in different Brazilian states ( = 0.146, = 0.467). CONCLUSION: This study indicates a distinct geographical distribution of IBDpatients at highest risk for COVID-19 complications in different states of the country, which may reflect contrasting socioeconomic, educational and healthcare aspects. No association between high risk of IBD and COVID-related mortality rates was identified.
